Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation

C. Voena, M. Malnati, I. Majolino, G. Fagà, V. Montefusco, L. Farina, A. Santoro, M. Ladetto, M. Boccadoro, P. Corradini

Research output: Contribution to journalArticlepeer-review

Abstract

Allogeneic stem cell transplantation (allo-SCT) is an effective and potentially curative treatment for some cases of multiple myeloma (MM). The curative efficacy of allo-SCT may be largely attributed to its immunological activity, the graft-versus-myeloma (GVM) effect. To evaluate the kinetics of residual myeloma cells, we analyzed the follow-up bone marrow samples of three MM patients by means of a real-time molecular assay. We identified a consistent correlation between onset of graft-versus-host disease and disease response. These data suggest that real-time molecular follow-up can be used to monitor the GVM effect and that it can be employed in the clinical setting to tailor post transplant immunomodulation.

Original languageEnglish
Pages (from-to)791-793
Number of pages3
JournalBone Marrow Transplantation
Volume32
Issue number8
DOIs
Publication statusPublished - Oct 2003

Keywords

  • Allogeneic transplantation
  • Graft-versus-myeloma
  • Multiple myeloma
  • Real-time PCR

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation'. Together they form a unique fingerprint.

Cite this